Lupin launches Doxycycline for Injection USP in the United States

Generic equivalent of Vibramycin for Injection, the drug is indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline and other antibacterial drugs

Lupin announced the launch of Doxycycline for Injection USP, 100 mg/Vial (Single-Dose Vial) in the United States, post approvals from the United States Food and Drug Administration (U.S. FDA). 

Doxycycline for Injection USP is a generic equivalent of Vibramycin for Injection, 100 mg/Vial of Pfizer, indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline and other antibacterial drugs. Doxycycline for Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the U.S. (IQVIA MAT April 2024).